In the US, Iclusig (ponatinib systemic) is a member of the following drug classes: BCR-ABL tyrosine kinase inhibitors, multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia.
Ingredient matches for Iclusig
Ponatinib is reported as an ingredient of Iclusig in the following countries:
Ponatinib hydrochloride (a derivative of Ponatinib) is reported as an ingredient of Iclusig in the following countries:
- United Kingdom
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.